Pembrolizumab is a medicine that helps the immune system fight cancer. This study is checking if adding another medicine, sacituzumab tirumotecan, can help adults with non-small cell lung cancer (NSCLC) after surgery. NSCLC is a type of lung cancer that can be removed by surgery. Sometimes, not all cancer cells are gone after surgery. Doctors want to see if the extra medicine helps keep the cancer away longer than using pembrolizumab alone. The study will compare how long patients stay free of cancer with each treatment.
Eligibility means who can join the study. To join, participants should have NSCLC and have not completely responded to surgery. They must also meet other health checks. Certain health conditions or past treatments may not allow participation.
- This study involves receiving pembrolizumab, and possibly sacituzumab tirumotecan, after surgery.
- Participants will be monitored for how long they stay cancer-free.
- There are specific health requirements and previous treatments that may affect eligibility.